These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30256029)

  • 41. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of intracytoplasmic sperm injection in patients with polycystic ovary syndrome or isolated polycystic ovaries.
    Esinler I; Bayar U; Bozdag G; Yarali H
    Fertil Steril; 2005 Oct; 84(4):932-7. PubMed ID: 16213846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum anti-Müllerian hormone levels are associated with early miscarriage in the IVF/ICSI fresh cycle.
    Liu X; Han Y; Wang X; Zhang Y; Du A; Yao R; Lv J; Luo H
    BMC Pregnancy Childbirth; 2022 Apr; 22(1):279. PubMed ID: 35366830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes.
    Ashrafi M; Hemat M; Arabipoor A; Salman Yazdi R; Bahman-Abadi A; Cheraghi R
    J Obstet Gynaecol; 2017 Jan; 37(1):82-88. PubMed ID: 27976974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of repetitive oocyte retrieval on the ovarian reserve: a retrospective cohort study.
    Marschalek J; Ott J; Aitzetmueller M; Mayrhofer D; Weghofer A; Nouri K; Walch K
    Arch Gynecol Obstet; 2019 May; 299(5):1495-1500. PubMed ID: 30790103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of anti-Müllerian hormone in female fertility and infertility - an overview.
    Grynnerup AG; Lindhard A; Sørensen S
    Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1252-60. PubMed ID: 22646322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
    Elgindy EA; El-Haieg DO; El-Sebaey A
    Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients.
    Aleyasin A; Aghahoseini M; Mokhtar S; Fallahi P
    Acta Med Iran; 2011; 49(11):715-20. PubMed ID: 22131240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome.
    Li Y; Nie M; Liu Y; Zhang W; Yang X
    Gynecol Endocrinol; 2015 Jun; 31(6):450-3. PubMed ID: 25585549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling.
    Pilsgaard F; Grynnerup AG; Løssl K; Bungum L; Pinborg A
    Acta Obstet Gynecol Scand; 2018 Sep; 97(9):1105-1113. PubMed ID: 29476703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
    Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
    Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of ovarian response with picoAMH in women undergoing controlled ovarian hyperstimulation.
    Bruno-Gaston J; Jung J; Kumar T; Zarutskie P; Gibbons W; Devaraj S
    Clin Biochem; 2021 Sep; 95():34-40. PubMed ID: 34000288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Impact of serum Anti-Mullerian Hormone levels on the results of assisted reproductive technologies. Single-center retrospective study from 2011 cycles (ICSI and bilateral tubal obstruction excluded)].
    Dosso N; Robin G; Catteau-Jonard S; Pigny P; Leroy-Billiard M; Dewailly D
    J Gynecol Obstet Biol Reprod (Paris); 2015 Jan; 44(1):63-71. PubMed ID: 24951378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes.
    Cela V; Obino MER; Alberga Y; Pinelli S; Sergiampietri C; Casarosa E; Simi G; Papini F; Artini PG
    Gynecol Endocrinol; 2018 Jun; 34(6):518-523. PubMed ID: 29271274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.